ElizabethCDeesMD

Oncology • Chapel Hill, NC

Associate Professor of Hematology & Oncology, University of North Carolina School of Medicine

Join to view full profile

Are you Dr. Dees?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 109 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
101 Manning Dr
Chapel Hill, NC 27514
Phone+1 919-966-4996

Fax+1 919-843-5515

Summary

Dr. Elizabeth Dees, MD is an oncologist in Chapel Hill, North Carolina. She is currently licensed to practice medicine in North Carolina and Maryland. She is affiliated with University of North Carolina Hospitals and is an Associate Professor of Hematology & Oncology at University of North Carolina School of Medicine.

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1996 - 1999
Brigham and Women's HospitalResidency, Internal Medicine, 1993 - 1996
Duke University School of MedicineClass of 1993

Certifications & Licensure

NC State Medical License 1999 - 2025
MD State Medical License 1996 - 2000
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Top MD Consumers Checkbook

Clinical Trials

S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. Start of enrollment: 2005 Jul 01
Completed
Phase 3
Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Start of enrollment: 2001 May 01
Completed
Phase 1, Phase 2
Vinflunine and Erlotinib or Pemetrexed in Treating Patients With Unresectable or Metastatic Solid Tumors Start of enrollment: 2006 Aug 01
Completed
Phase 1
Lapatinib and Radiation Therapy in Treating Patients With Locally Recurrent or Chemotherapy-Refractory Locally Advanced or Metastatic Breast Cancer Start of enrollment: 2006 Apr 01
Completed
Phase 1
Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors Start of enrollment: 2007 Sep 01
Completed
Phase 1
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
Study of BKM120 or BYL719 and Capecitabine in Patients With Metastatic Breast Cancer Start of enrollment: 2011 Aug 01
Completed
Phase 1
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Start of enrollment: 2011 Jun 20
Active, not recruiting
Phase 1
Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women Start of enrollment: 2014 Mar 11
Completed
Phase 2
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Start of enrollment: 2013 Oct 02
Completed
Phase 2
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer Start of enrollment: 2014 May 19
Completed
Phase 1
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer Start of enrollment: 2017 May 04
Completed
Phase 1
A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer Start of enrollment: 2019 Feb 13
Withdrawn
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Quality of Life Outcomes in Breast Cancer Patients Receiving Chemotherapy With or Without Radiation Therapy.
Ryan T Morse, Nathan W Bean, Jacob Hall, Allison Deal, Kirsten A Nyrop
Clinical Breast Cancer. 2024-08-30
2 citations
Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
Elizabeth C Wescott, Xiaopeng Sun, Paula Gonzalez-Ericsson, Ann Hanna, Brandie C Taylor
Cancer Research Communications. 2024-04-24
6 citations
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer.
Brandie C Taylor, Xiaopeng Sun, Paula I Gonzalez-Ericsson, Violeta Sanchez, Melinda E Sanders
Cancer Discovery. 2024-02-08

Grant Support

Clinical Trial: Lccc 0509: A Two-Arm Phase I Dose Escalation Trial Of VinflunineNational Center For Research Resources2008
MLN8054, Aurora A Kinase Inhibitor In Patients With Advanced Solid TumorNational Center For Research Resources2007
Lccc 0509: A Two-Arm Phase I Dose Escalation Trial Of VinflunineNational Center For Research Resources2007
Calgb 60301: Sorafenib For Solid Tumors And Ham MalignanciesNational Center For Research Resources2006–2007
Phase I Radiosensitization Study Of GW572016 In Recurrent Breast CancerNational Cancer Institute2006–2007
Combination Of Pegylated Liposomal Doxil With PS-341 In Patients With MalignancNational Center For Research Resources2005–2007
P450 Phenotype And Chemotherapy Toxicity In The ElderlyNational Center For Research Resources2002–2006
Relationship Between Paclitaxel Pharmacokinetics And Phenotypic MarkersNational Center For Research Resources2004
NSABP P-1: Trial To Determine Worth Of Tamoxifen For Preventing Breast Cancer.National Center For Research Resources2004

Professional Memberships

American Society of Clinical Oncology - ASCO
Member